Centrifuge

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Retrieved on: 
Monday, April 22, 2024
TRACER, Histology, Mouse, Phenotype, Data science, Cell, AAV, CNS, Machine learning, Senior, Tauopathy, Gene, Process, Society, BBB, ALS, Central nervous system, Public, HEK293, Therapy, Centrifuge, SOD1, Vaccine

“Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.

Key Points: 
  • “Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.
  • Three of those programs now have development candidates selected, and we see the potential for them to enter clinical trials next year,” said Todd Carter, Ph.D., Chief Scientific Officer of Voyager Therapeutics.
  • ET
    Intravenous administration of BBB-penetrant, MAPT-Silencing, AAV gene therapy provides broad and robust CNS Tau lowering in tauopathy mouse models (#1602).
  • ET
    Intravenous delivery of AAV gene therapy for the treatment of SOD1-ALS provides broad SOD1 lowering in NHP (#1647).

Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Genetics, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Exosome, EV, Plasma, ACE, Serum, Patient, RNA, DNA, Cancer, Personalized medicine, MD, Fluid mechanics, Doctor of Philosophy, AACR, Genomics, Prognosis, Biology, Centrifuge, Pharmaceutical industry

Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
  • ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
  • “Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” said Paul R. Billings, MD, Ph.D., CEO and Chairman of Biological Dynamics.
  • Biological Dynamics will showcase ExoVerita Pro in Booth #4340 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10.

Global Industrial Centrifuges Business Report 2023: Market to Reach $10.3 Billion by 2030 - U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 7% CAGR

Retrieved on: 
Wednesday, January 3, 2024
Investment, Mining, Growth, Centrifuge

DUBLIN, Jan. 2, 2024 /PRNewswire/ -- The "Industrial Centrifuges - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 2, 2024 /PRNewswire/ -- The "Industrial Centrifuges - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Industrial Centrifuges estimated at US$7.3 Billion in the year 2022, is projected to reach a revised size of US$10.3 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030.
  • In the context of competition, the report offers insights into the global industrial centrifuges market, including the percentage market share of key competitors in 2023.
  • The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 7% CAGR
    The Industrial Centrifuges market in the U.S. is estimated at US$2 Billion in the year 2022.

Biological Dynamics Announces Early Access Program to Its ExoVerita™ Pro Platform

Retrieved on: 
Wednesday, November 8, 2023
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Plasma, Extracellular vesicle, AMP, RNA, Special access program, Exosome, Conference, ACE, Cell, DNA, Glossary of biology, Biological Dynamics of Forest Fragments Project Area of Relevant Ecological Interest, Disease, Centrifuge, Annual general meeting, Serum, Cancer, Diagnosis, Prognosis, Fluid mechanics, Pharmaceutical industry

Biological Dynamics, Inc. , the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.

Key Points: 
  • Biological Dynamics, Inc. , the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.
  • “Technology is revolutionizing our understanding and management of some of our most challenging diseases,” said Paul R. Billings, M.D., Ph.D., CEO and Director of Biological Dynamics.
  • Biological Dynamics’ ExoVerita technology platform offers an automated workflow for successfully detecting and recovering exosomes that have benefits over other methods, such as ultracentrifugation and column purification.
  • Biological Dynamics will showcase its Early Access Program and products at the Association for Molecular Pathology (AMP) Annual Meeting in Salt Lake City, Utah, Nov. 14-18, and will debut ExoVerita Pro at the SelectBio Conference in Laguna Hills, Calif., Nov. 28-30.

Industrial Centrifuges Global Strategic Business Report 2023: Market to Reach $10.3 Billion by 2030 - Robust Consumption of Processed Foods & Ensuing Rise in Investments - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Food Tech, Retail, Chemicals, Plastics, Technology, Manufacturing, Food, Beverage, Wastewater, Growth, Expansion plans for Milton Keynes, Centrifuge, Prevalence, Investment, Medication, Mining, Pet industry

The "Industrial Centrifuges - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Industrial Centrifuges - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Industrial Centrifuges estimated at US$7.3 Billion in the year 2022, is projected to reach a revised size of US$10.3 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2022-2030.
  • Sedimentation, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$6.8 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 7% CAGR
    The Industrial Centrifuges market in the U.S. is estimated at US$2 Billion in the year 2022.

Thermo Fisher Scientific Recognized by R&D 100 Awards for Innovations in Science and Technology

Retrieved on: 
Friday, September 8, 2023
Technology, Research, Medical Devices, Other Technology, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Vaccine, Hybrid vehicle, Multimedia, Thermo Fisher Scientific, Cell, Antibody, Proteomics, CTS, Thermo, Protein, Metabolomics, R, Centrifuge, Mindful Scientific Inc., Orbitrap, Fine chemical

Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards , honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, has been recognized by the R&D 100 Awards , honoring the top 100 revolutionary products in science and technology from around the world, for three unique innovations that aid researchers’ and scientists’ work in a variety of life science applications, including bioproduction and small-molecule analysis.
  • “With a mission to enable our customers to make the world healthier, cleaner and safer, we’re committed to scientific advancement,” said Karen Nelson, chief scientific officer, Thermo Fisher Scientific.
  • Established in 1963, the R&D 100 Awards is the only science and technology awards competition that recognizes new commercial products, technologies and materials for their technological significance.
  • Sponsored by R&D World Magazine, the R&D 100 Awards recognize and celebrate the 100 most innovative technologies of the previous year.

Industry Leaders Announce Groundbreaking Tokenized Asset Coalition

Retrieved on: 
Thursday, September 7, 2023
Professional Services, Technology, Blockchain, Cryptocurrency, Finance, Banking, Coalition, Organization, Ecosystem, TAC, Trust, Decentralized finance, Create, Education, Environment, Centrifuge, Circle

The Tokenized Asset Coalition (TAC) launched today with industry leaders including Aave Companies , Centrifuge , Circle , Coinbase , Base , Credix , Goldfinch and RWA.xyz as founding members.

Key Points: 
  • The Tokenized Asset Coalition (TAC) launched today with industry leaders including Aave Companies , Centrifuge , Circle , Coinbase , Base , Credix , Goldfinch and RWA.xyz as founding members.
  • The Tokenized Asset Coalition champions the adoption of public blockchains, asset tokenization and institutional DeFi to dramatically alter the way capital is formed, invested and managed on-chain, paving the way for a more open, fair and transparent system for investors.
  • The Tokenized Asset Coalition has three primary objectives:
    Education: Create and disseminate educational content, host events, facilitate analysis and share insights about asset tokenization to foster trust and understanding within the ecosystem.
  • The Tokenized Asset Coalition believes that public crypto rails offer superior efficiency, cost savings and transparency compared to legacy systems.

Flash News: OKX Ventures Report Explores the Potential of Real-World Assets in the DeFi Space

Retrieved on: 
Friday, July 21, 2023
RWA, Centrifuge, Maple, Web3, Elis James, Research, OKX, Cryptocurrency, Decentralized finance

OKX Ventures has published a new report, entitled: 'Embrace All Markets: How Does Real-World Assets (RWA) Help DeFi Swallow the World?'

Key Points: 
  • OKX Ventures has published a new report, entitled: 'Embrace All Markets: How Does Real-World Assets (RWA) Help DeFi Swallow the World?'
  • The report explores the integration and evolution of DeFi and TradFi, with a focus on the challenges and opportunities facing the integration of traditional RWAs into the DeFi space.
  • OKX Venture's research piece also identifies several challenges currently facing the DeFi-RWA space, including:
    Despite these challenges, OKX Ventures' research piece acknowledges the advantages of tokenizing RWAs, highlighting its potential for speculators, institutions, DeFi projects and fundraising.
  • OKX Ventures further proposed several criteria for determining the success of RWA adoption in the DeFi space, including (but not limited to):

Reapplix wins 2023 Frost & Sullivan's Best Practices Technology Innovation Leadership Award

Retrieved on: 
Thursday, July 20, 2023
CE, Diabetes, Life, U.S. FDA, Neeraj, Patient, Blood, Coagulation, Centrifuge, Frost, Industry analyst, Pharmaceutical industry

BIRKEROD, Denmark, July 20, 2023 /PRNewswire-PRWeb/ -- Reapplix, a leading company specializing in the biological treatment and management of chronic wounds, today announced it has been awarded a Best Practices Technology Innovation Leadership Award in chronic wound treatment for patients with diabetes by Frost & Sullivan.

Key Points: 
  • BIRKEROD, Denmark, July 20, 2023 /PRNewswire-PRWeb/ -- Reapplix, a leading company specializing in the biological treatment and management of chronic wounds, today announced it has been awarded a Best Practices Technology Innovation Leadership Award in chronic wound treatment for patients with diabetes by Frost & Sullivan.
  • Frost & Sullivan's Technology Innovation Leadership Award recognizes the company that has introduced the best underlying technology for achieving remarkable product and customer success while driving future business value.
  • "We are so honored to receive this recognition from Frost & Sullivan," said Kira Rupprecht, Chief Executive Officer at Reapplix.
  • Each year, Frost & Sullivan applies a rigorous analytical process to evaluate multiple nominees for each award category before determining the final award recipient.

DeFi protocol AlloyX Raises $2M Pre-Seed Round, Launches Aggregation Platform for $530M+ RWA Loans On Chain

Retrieved on: 
Thursday, June 29, 2023
Professional Services, Blockchain, Technology, Cryptocurrency, Web3, Finance, Fintech, Dame Alice Owen's School, RWA, Decentralized finance, Venture, Stratos, United States Treasury security, Investment, Risk, TVL, Centrifuge, Digital Currency Group

As a result, investors such as decentralized autonomous organizations (DAOs) can gain access to liquidity, yield and diversification in tokenized credit.

Key Points: 
  • As a result, investors such as decentralized autonomous organizations (DAOs) can gain access to liquidity, yield and diversification in tokenized credit.
  • Compared to crypto loans or liquidity pools, tokenized credit investments typically carry an initial lockup period and lower liquidity.
  • Using AlloyX, investors and DeFi protocols can create strategies blending tokenized U.S. T-bills with the highest volume and deepest liquidity of RWA available to achieve attractive yields.
  • 1 Funding raised in pre-seed round is part of AlloyX Inc. to build the AlloyX protocol, the DeFi project that aggregates tokenized credit.